Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myeloablative vs Nonmyeloablative Transplant Conditioning in MDS or AML
NCT00322101Phase 3Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jan 2006
- Primary completion
- Apr 2012
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
A Phase 3 trial of fludarabine, busulfan, cyclophosphamide in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Fred Hutchinson Cancer Center. Started Jan 2006; status: completed.
02
Drugs
fludarabinebusulfancyclophosphamide
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00322101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322101.